Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2024-05-22

Clinical Trial Update: Tenecteplase in Stroke Patients Between 4.5 and 24 Hours [Phase 3]

View source ↗

Summary

Phase 3 trial results for tenecteplase in ischemic stroke patients treated 4.5 to 24 hours after onset have completed, with results posted in May 2024.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Tenecteplase (tenecteplase)

Snippet

Sponsor: Genentech, Inc. | Conditions: THROMBOLYSIS | Phase 3 | Status: COMPLETED | Results posted: 2024-05-22